Implementation of Pharmacogenetic Testing as Part of Medication Reviews in Hospital Wards
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Admitted Multimorbid Patients
- Sponsor
- Hospital Pharmacy Enterprise, South Eastern Norway
- Enrollment
- 46
- Locations
- 1
- Primary Endpoint
- Number of patients with results from pharmacogenetic testing included in medication review
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
The purpose of this study is to investigate whether it is feasible to implement pharmacogenetic testing as part of medication review while the patient is admitted to hospital.
Detailed Description
Earlier studies have shown that pharmacogenetic testing may contribute to optimizing the efficacy of medication treatment and to reduce the risk of adverse effects. Inclusion of pharmacogenetic testing as part of medication reviews reveals more serious drug related problems and leads to more changes in medication treatment than medication review alone. The use of pharmacogenetic testing as part of medication reviews has not earlier been systematically investigated in hospital patients in Norway. There is little documentation of what is needed to implement the use of pharmacogenetic testing in a hospital ward. The investigators are conducting a descriptive study in two internal medicine wards at Akershus University Hospital. 50 patients using minimum 5 regular drugs including at least one relevant for pharmacogenetic testing will be enrolled in the study.
Investigators
Eligibility Criteria
Inclusion Criteria
- •at least 2 long-term conditions
- •at least 5 regular drugs of which at least one relevant for pharmacogenetic testing
- •at least 2 years life expectancy
- •able to communicate in Norwegian
- •able to give informed consent
- •summary care record
Exclusion Criteria
- •moderate to severe dementia
Outcomes
Primary Outcomes
Number of patients with results from pharmacogenetic testing included in medication review
Time Frame: from admission to discharge, an average of 1 week
Number of patients
Secondary Outcomes
- Acceptance of recommendations(after medication review and before discharge, an average of 3 days)
- Documentation of information from pharmacogenetic testing(after medication review and before discharge, an average of 3 days)